Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 44, 2014 - Issue 11
346
Views
11
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats

, , , , , , , , , , , , & show all
Pages 996-1008 | Received 04 Apr 2014, Accepted 18 May 2014, Published online: 09 Jun 2014
 

Abstract

1. The biotransformation and disposition of tivantinib in humans, dogs and rats was examined after a single oral administration of [14C]tivantinib. Tivantinib constituted no more than one-third of the plasma radioactivity in all species, demonstrating significant contribution of the metabolites to plasma radioactivity. The major circulating metabolites in all species were M4 and M5, hydroxylated metabolites at the benzyl position of the tricyclic ring, accounting for 19.3 and 12.2% of the AUC of the total radioactivity, respectively, in humans.

2. The majority of radioactivity was excreted to the feces via bile. Tivantinib was detected at trace levels in urine, feces and bile, demonstrating extensive metabolism prior to biliary excretion and nearly complete tivantinib absorption under fed conditions.

3. Seven metabolic pathways were identified for tivantinib and included six oxidations (M4, M5, M7, M8, M9 and M11) and one glucuronidation (M23). The major metabolic and excretory pathways were found to be common among all species. Species differences in the metabolic pathways included lactam metabolite (M8) formation in humans and dehydrogenated metabolite (M11) formation in animals.

4. None of the metabolites identified in this work are believed to significantly impact the efficacy or toxicity of tivantinib in humans.

Acknowledgements

We thank Drs. Satoru Ohsuki, Yuji Iwano and Takanori Yasukochi for synthetic standards of metabolites at Daiichi Sankyo RD Novare Co., Ltd. We are also grateful to Drs. Terence Hall, Yunxia Wang, and Darin Kizer for exploratory metabolite identification work at ArQule, Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.